# Sources Index — alzhub.org research library Every URL below was actually opened (directly, or via the `r.jina.ai` reader proxy when a site blocked automated access) and its content read before any fact was extracted from it, per the project's honesty rules. Grouped by source type. Cross-reference with `studies.json`, `news.json`, and `stats.json` for the specific claims each source supports. ## Government / regulatory agencies - FDA — Press Announcements & Drug Safety Communications - https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease - https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval - https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease - https://www.fda.gov/drugs/drug-safety-communications/fda-recommend-additional-earlier-mri-monitoring-patients-alzheimers-disease-taking-leqembi-lecanemab - Biogen investor-relations press releases (substituted where FDA.gov had removed/archived the original 2021/2023 release pages) - https://investors.biogen.com/news-releases/news-release-details/fda-grants-accelerated-approval-aduhelmtm-first-and-only - https://investors.biogen.com/news-releases/news-release-details/fda-approves-leqembitm-lecanemab-irmb-under-accelerated-approval - https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise - European Medicines Agency (EMA) - https://www.ema.europa.eu/en/news/leqembi-recommended-treatment-early-alzheimers-disease - https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2024 - https://www.ema.europa.eu/en/medicines/human/EPAR/kisunla - CMS (Centers for Medicare & Medicaid Services) - https://www.cms.gov/medicare/coverage/coverage-evidence-development/monoclonal-antibodies-directed-against-amyloid-treatment-alzheimers-disease-ad - https://www.cms.gov/newsroom/blog/guiding-improved-dementia-experience-clearing-path-comprehensive-high-quality-dementia-care - CDC / NCHS - https://www.cdc.gov/nchs/products/databriefs/db521.htm - https://www.cdc.gov/nchs/fastats/alzheimers.htm - NIH RePORT (categorical spending) - https://report.nih.gov/funding/categorical-spending/ - NIA (National Institute on Aging) budget justification (via Wayback Machine archive; live page is bot-gated) - http://web.archive.org/web/20260802081505/https://www.nia.nih.gov/about/budget/fiscal-year-2025-budget - WHO - https://www.who.int/news-room/fact-sheets/detail/dementia - ClinicalTrials.gov (API v2 record) - https://clinicaltrials.gov/api/v2/studies/NCT04777396 ## Peer-reviewed journals (PubMed / PMC / publisher sites) - JAMA — https://pubmed.ncbi.nlm.nih.gov/39068545/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC10352931/ ; https://pubmed.ncbi.nlm.nih.gov/40720610/ - Alzheimer's & Dementia — https://pubmed.ncbi.nlm.nih.gov/38934362/ ; https://pubmed.ncbi.nlm.nih.gov/38491912/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC11848338/ ; https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70987 ; https://pmc.ncbi.nlm.nih.gov/articles/PMC12263344/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC11667504/ ; https://pmc.ncbi.nlm.nih.gov/articles/PMC12761895/ (Innovation in Aging supplement) - Nature / Nature Medicine / Nature Communications / npj Dementia — https://www.nature.com/articles/s41591-025-03622-w ; https://www.nature.com/articles/s41591-024-02931-w ; https://www.nature.com/articles/s41467-021-22354-2 ; https://www.nature.com/articles/s41586-025-09662-z ; https://www.nature.com/articles/s41467-026-68374-8 ; https://pmc.ncbi.nlm.nih.gov/articles/PMC12411272/ - The Lancet / Lancet Neurology — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60461-5/abstract ; https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00227-3/abstract ; https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00459-9/fulltext ; https://chronicdisease.org/wp-content/uploads/2024/12/Lancet-2024.pdf (Lancet Commission 2024 full report PDF, hosted mirror) - New England Journal of Medicine — https://pubmed.ncbi.nlm.nih.gov/36449413/ - Journal of Prevention of Alzheimer's Disease — https://www.jpreventionalzheimer.com/9231-editorial-on-the-2024-alzheimers-association-criteria-still-not-ready-for-clinical-use.html ; https://pubmed.ncbi.nlm.nih.gov/35542991/ - Annals of Medicine and Surgery — https://pmc.ncbi.nlm.nih.gov/articles/PMC12889242/ - Alzheimer's Research & Therapy — https://link.springer.com/article/10.1186/s13195-026-01969-x - Neurology — https://pubmed.ncbi.nlm.nih.gov/39819096/ ; https://pubmed.ncbi.nlm.nih.gov/17101889/ - Ophthalmology — https://pubmed.ncbi.nlm.nih.gov/38336283/ - Brain — https://academic.oup.com/brain/article/147/7/2368/7558436 - eLife — https://elifesciences.org/articles/62199 - Acta Neuropathologica — https://pmc.ncbi.nlm.nih.gov/articles/PMC7520051/ - Science (glymphatic review; corroborated via secondary sources — see RESEARCH_LOG) — https://pubmed.ncbi.nlm.nih.gov/33004510/ - Annals of Internal Medicine — https://www.acpjournals.org/doi/10.7326/0003-4819-145-10-200611210-00005 - JAMA (mortality/caregiver-burden reviews) — https://pubmed.ncbi.nlm.nih.gov/10605972/ ; https://pubmed.ncbi.nlm.nih.gov/24618967/ - Psychology and Aging — https://pubmed.ncbi.nlm.nih.gov/12825775/ - Cochrane Database of Systematic Reviews — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004396.pub3/full - Journal of the American Geriatrics Society — https://pmc.ncbi.nlm.nih.gov/articles/PMC12645538/ ## Nonprofit / advocacy organizations - Alzheimer's Association (alz.org, aaic.alz.org) — Facts and Figures reports, press releases, AAIC conference results - https://pmc.ncbi.nlm.nih.gov/articles/PMC12040760/ (2025 Facts and Figures, peer-reviewed full article) - https://www.alz.org/getmedia/c05f7ba4-9aea-4cb0-8898-5e8bff3f0930/executive-summary-2025-alzheimers-disease-facts-and-figures.pdf - https://www.alz.org/wi/news/facts-and-figures-2025 - https://www.alz.org/news/2026/facts-figures-report-brain-health - https://www.alz.org/news/2025/fda-action-approving-leqembi-subcutaneous-maintenance-dosing - https://www.alz.org/news/2025/senate-appropriations-committee-approves-100-million-increase-alzheimers-research - https://www.alz.org/news/2025/alzheimers-association-statement-oral-semaglutide-phase-3-topline-data-release - https://www.alz.org/news/2025/house-introduces-bipartisan-legislation-asap-act-alzheimers-screening - https://www.alz.org/news/2025/alzheimers-association-center-for-dementia-respite-innovation-grants-4-million-in-second-year - https://www.alz.org/news/2026/100-million-dollar-alzheimers-dementia-research-signed-law - https://aaic.alz.org/releases-2025/us-pointer-study-results-announced.asp - Alzheimer's Disease International (ADI) - https://www.alzint.org/news-events/news/lancet-commission-identifies-two-new-risk-factors-for-dementia-and-suggests-45-of-cases-could-be-delayed-or-reduced/ - https://www.alzint.org/news-events/news/european-commission-approves-first-disease-modifying-treatment-for-alzheimers-disease-in-the-eu/ ## News outlets - STAT News — https://www.statnews.com/2025/11/24/alzheimers-disease-johnson-and-johnson-posdinemab/ ; https://www.statnews.com/2025/11/03/exercise-slows-alzheimers-progression-journal-nature-medicine-study/ ; https://www.statnews.com/2024/11/25/cassava-sciences-simufilam-trial-failure/ ; https://www.statnews.com/2026/01/20/nih-funding-deal-trump-cuts-rejected-budget-boosted-415-million/ - Scientific American — https://www.scientificamerican.com/article/lifesaving-alzheimers-research-delayed-by-trump-funding-cuts/ - Clinical Trials Arena — https://www.clinicaltrialsarena.com/news/alzheon-alzheimers-pill-misses-phase-iii/ - PharmExec — https://www.pharmexec.com/view/fda-approves-label-update-eli-lilly-kisunla-reduce-aria-e-risk-early-alzheimer-disease-treatment - Association of Health Care Journalists (healthjournalism.org) — https://healthjournalism.org/blog/2026/04/a-simple-blood-test-could-detect-alzheimers-earlier-but-medicare-doesnt-cover-it/ ## Company / institutional newsrooms - Roche — https://www.roche.com/media/releases/med-cor-2025-07-28 - Quest Diagnostics — https://newsroom.questdiagnostics.com/2025-04-09-Quest-Diagnostics-Launches-New-AD-Detect-TM-Blood-Test-to-Aid-in-Confirming-Alzheimers-Disease - C2N Diagnostics (via BioSpace wire) — https://www.biospace.com/press-releases/fda-clears-c2n-diagnostics-precivityad2-first-alzheimers-blood-test-for-adults-with-cognitive-symptoms-as-young-as-40 - UCB — https://www.ucb.com/newsroom/press-releases/article/ucb-presents-encouraging-data-on-bepranemab-in-early-alzheimer-s-disease-in-phase-2a-study-at-ctad-2024 - UCLA newsroom — https://sciences.ugresearch.ucla.edu/2025/08/28/potential-stroke-and-dementia-therapies-along-with-oral-health-discoveries-put-on-hold-at-ucla ## Notes on verification method - Sources marked "via r.jina.ai" in agent reports were retrieved through the `https://r.jina.ai/` reader proxy (with a curl User-Agent) because the origin site blocked direct automated fetches. - Two items rely on corroboration rather than a direct full-text read of the primary source (flagged explicitly in `studies.json` and in `RESEARCH_LOG.md`): the Nedergaard & Goldman 2020 *Science* glymphatic review (paywalled even via proxy) and specific percentage figures from the Lancet Commission 2024 results table (PDF fetch confirmed the risk-factor list and methodology but not every downstream percentage independently). - A number of leads were found via search but could not be opened/verified and were excluded outright; see `RESEARCH_LOG.md` for the full list per research track.